



Clinical trial results:

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies

Summary

EudraCT number	2017-004603-52
Trial protocol	DK HU ES AT FI DE CZ GB IT
Global end of trial date	04 October 2021

Results information

Result version number	v1 (current)
This version publication date	09 August 2022
First version publication date	09 August 2022

Trial information

Trial identification

Sponsor protocol code	SGI-110-12
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03603964
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Astex Pharmaceuticals, Inc,
Sponsor organisation address	4420 Rosewood Drive, Suite 200, Pleasanton, United States, 94588
Public contact	Clinical trial info SGI-110-012, Astex Pharmaceuticals, Inc., clinicaltrials@astx.com
Scientific contact	Clinical trial info SGI-110-012, Astex Pharmaceuticals, Inc., clinicaltrials@astx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 October 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 October 2021
Global end of trial reached?	Yes
Global end of trial date	04 October 2021
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To provide ongoing treatment with guadecitabine for subjects who benefited from guadecitabine treatment in a previous Astex-sponsored clinical study and to obtain long-term safety information.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Finland: 1
Country: Number of subjects enrolled	Czechia: 1
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 2
Country: Number of subjects enrolled	Japan: 6
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Korea, Republic of: 2
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	United States: 8
Worldwide total number of subjects	35
EEA total number of subjects	14

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2
From 65 to 84 years	29
85 years and over	4

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled in the study at 32 study centers in the United States, Spain, Italy, Canada, Japan, France, Germany, Poland, Finland, South Korea, Taiwan, Czech Republic and Australia from 18 July 2018 to 30 November 2020.

Pre-assignment

Screening details:

35 subjects who had participated in a previous Astex-sponsored guadecitabine clinical study (SGI-110-01 {NCT01261312}, SGI-110-04 {NCT02348489}, SGI-110-06 {NCT02920008}, and SGI-110-07 {NCT02907359}) and were still benefitting from the treatment at the time of database close of the original study, were enrolled in this extension study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Guadecitabine
-----------	---------------

Arm description:

Subjects received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle, at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.

Arm type	Experimental
Investigational medicinal product name	Guadecitabine
Investigational medicinal product code	
Other name	SGI-110
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

SC injection administered on Days 1-5 of each 28-day cycle up to a maximum of 26 cycles.

Number of subjects in period 1	Guadecitabine
Started	35
Completed	0
Not completed	35
Study terminated by Sponsor	19
Death	9
Withdrawal by subject	7

Baseline characteristics

Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	35	35	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	75.3 ± 11.2	-	
Gender categorical Units: Subjects			
Female	15	15	
Male	20	20	
Ethnicity Units: Subjects			
Hispanic or Latino	4	4	
Not Hispanic or Latino	29	29	
Not reported	2	2	
Race Units: Subjects			
White	24	24	
Asian	10	10	
Not reported	1	1	

End points

End points reporting groups

Reporting group title	Guadecitabine
Reporting group description: Subjects received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle, at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.	

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs) ^[1]
-----------------	--

End point description:

Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE can therefore be any unfavourable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs are defined as events that occur or worsen on or after the date of the first study treatment (Cycle 1 Day 1 {C1D1}) until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment, whichever occurs first. Safety population included all subjects who received any amount of study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From the start of study treatment until 30 days after the last dose of study treatment or prior to the subject receiving alternative anticancer therapy, whichever occurs first

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypotheses were tested for this end point.

End point values	Guadecitabine			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: subjects	35			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival

End point title	Overall Survival
-----------------	------------------

End point description:

Overall survival was defined as the number of days from the time of randomisation in the prior study to the date of death (regardless of cause). Subjects without a documented death date at the time of analysis were censored at the last date known alive. Survival time in days = (earliest of date of death or censoring) – (randomisation date in the prior study). Efficacy population included all subjects who received any amount of study treatment. 99999 indicates that the data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomisation in the prior study to the date of death

End point values	Guadecitabine			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: days				
median (confidence interval 95%)	2583.0 (1422.0 to 99999)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From the start of study treatment until 30 days after the last dose of study treatment or prior to the subject receiving alternative anticancer therapy, whichever occurs first.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Guadecitabine
-----------------------	---------------

Reporting group description:

Participants received guadecitabine, SC injection on Days 1-5 of each 28-day cycle, at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No formal statistical hypotheses were tested for this end point.

Serious adverse events	Guadecitabine		
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 35 (42.86%)		
number of deaths (all causes)	9		
number of deaths resulting from adverse events	1		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatic neoplasm			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Injury, poisoning and procedural complications			
Patella fracture			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cognitive disorder			

subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	7 / 35 (20.00%)		
occurrences causally related to treatment / all	8 / 10		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease			
subjects affected / exposed	1 / 35 (2.86%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Guadecitabine		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 35 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated due to the discontinuation of the overall guadecitabine development program, and not due to subject safety.
--

Notes: